

## Depression Market Forecast

---

Product Type: Interactive Model (7 pages)

Published by: Datamonitor

Single user price: \$6400.00

Product Code: HC00076-009

Published on: 19 January 2012

Multi-user price: \$16000.00

---

New product launches across the seven major markets will see the market expand incrementally to 2020, reinforcing the depression market's status as one of the largest of the CNS disorders. Lu AA21004 (Lundbeck/Takeda) will become the highest-selling drug, after negative clinical trial data for TC-5214 (Targacept/AstraZeneca) and the discontinuation of Valdoxan (agomelatine; Servier) in the US.

### Scope of this research

- Access Datamonitor's patient-based depression market forecast in the seven major markets, with transparent methodology and clear assumptions.
- Evaluate a highly granular forecast with sales value and volume projections to 2020 at the country, class, product, and regimen level.
- Understand depression market dynamics, and which factors will lead to commercial success.
- Review the products Datamonitor forecasts to launch over the next ten years, and how each subsequent launch will shape the market.

### Research and analysis highlights

Datamonitor forecasts the seven major depression markets to grow to \$12.0bn by 2020 at a compound annual growth rate of 0.9%. This incremental growth is expected to come from uptake of new product launches and will offset increasing generic erosion of the market value.

By 2020, sales of the leading depression drug classes, such as the SSRI and SNRI antidepressants, are expected to decline. Conversely, sales of non-traditional antidepressants are projected to rise from \$1.4bn in 2010 to \$3.5bn in 2020.

Sales of currently marketed products are forecast to decrease three-fold over 2010–20, as the saturation of the depression market with generics increases. Nevertheless, Datamonitor expects new pipeline drugs to capture a sizable share of the market, with predicted total sales of \$3.9bn in 2020 equating to a market share of 24.3%.

### Key reasons to purchase this research

- Which products stand to benefit from the expected failure of TC-5214 to reach the market?
- What are the implications to the US market following Novartis's discontinuation of agomelatine development?
- What degree of commercial success does Datamonitor forecast for key pipeline drugs?
- What will the overall depression market dynamics be over the next 10 years?
- How will sales of the major drug classes in depression evolve during the forecast period?

## Depression Market Forecast

---

Product Type: Interactive Model (7 pages)

Published by: Datamonitor

Single user price: \$6400.00

Product Code: HC00076-009

Published on: 19 January 2012

Multi-user price: \$16000.00

---

### Table of contents

#### OVERVIEW

Summary

#### OVERVIEW

This product contains forecasts for depression drugs across the seven major markets from 2010 to 2020. It has been designed for delivery in an excel data pack format, but for more detail about depression please see the accompanying Market and Product Forecasts: Depression word document and PowerPoint executive presentation (HC00076-003).

The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.

Please select the data pack option from the download menu at the side of the page to access the model.

Introduction

Features and benefits

Research and analysis highlights

Key questions answered

Forecasting Methodology

Disclaimer

#### FIGURES

Figure: Patient-based forecast methodology for depression, 2011

## Depression Market Forecast

---

Product Type: Interactive Model (7 pages)

Published by: Datamonitor

Single user price: \$6400.00

Product Code: HC00076-009

Published on: 19 January 2012

Multi-user price: \$16000.00

---

# YES, I WOULD LIKE TO PURCHASE NOW

Fax back this form to

+44 161 238 4141 (Global)

Please select the licence type (learn more)

\$6400.00 (Single user licence)     \$16000.00 (multi-user licence)

### Complete your details

Title    Mr     Mrs     Ms

Name

Job Title

Department

Company

Address

State/Province

Country                       Post Code/ZIP

Email

Tel                                       Fax

Please sign below to confirm your order

Date

### Complete payment details

Tick here to confirm you wish to be invoiced for this item

Please supply purchase order number or enter N/A:

---

If you are an EU company (except UK) please supply your VAT / BTW/ MOMS / MWST/ IVA / FPA number

---

If you wish to pay by credit card please complete your [purchase online](#)

Or call us on:

+44 161 238 4085 (EU)

+61 2 8705 6900 (AP)

+1 212 686 7400 (US)

Please do not add any credit card details on this form

This product is delivered in electronic format. If you require hard copy format please [contact us](#).  
To view the terms and conditions related to the sale of this product please [click here](#).